Inventors and founders of Lytix Biopharma in NRK’s Schrödingers Katt. Watch the programme in Norwegian.

Novel antimicrobial and cancer drugs

Lytix Biopharma AS is a privately-owned pharmaceutical company focussed on anti-microbials and cancer therapeutics.

The Company develops novel antimicrobial peptide-based drugs for the treatment of resistant bacterial and fungal infections, as well as first-in-class oncology treatments.

Receive newsletter

Lytix Biopharma newsletter click here
Oslo, Norway and Seoul, Korea, June 09, 2010:
- Lytix Biopharma and KAEL–GemVax announce approval of joint clinical trial
Read more
May 20, 2010:
- Update on the Phase I clinical trials of Oncopore™ (LTX-315) for the treatment of cancer.
Read more
May 20, 2010:
- Approval by the Swedish Medical Products Agency to commence a Phase I/IIa clinical trial
Read more
May 04, 2010:
- General Assembly of Shareholders on 4th June 2010
Read more
Go to news archive >